Introduction
Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with an estimated prevalence of 2-5 per 1000 [1, 2] that is characterized by cardiac impairment linked to increased left ventricular wall thickness, diastolic dysfunction, interstitial fibrosis and myocyte disarray [3, 4] . Clinical presentation of HCM patients is heterogeneous, ranging from asymptomatic or mildly symptomatic, to distinct features such as dyspnea, angina, syncope, leading in some cases to progressive heart failure [1, 5, 6] . HCM is a genetic autosomal dominant disease characterized by extensive allelic heterogeneity affecting both sarcomeric and sarcomere-related proteins. Variants of the cardiac myosin binding protein C3 (c-MYBPC3) gene encoding the sarcomeric protein MyBP-C are the most common genetic cause of HCM, representing 40-50% of all HCM mutations [1, 7, 8] . Variants with different pathogenicity classification are associated with heterogeneous HCM clinical presentation, disease onset and prognosis [9] [10] [11] [12] [13] . Thus, analysis of structural-functional correlations is necessary to understand the molecular mechanisms by which these variants lead to HCM. It has been hypothesized that c-MYBPC3 missense mutations directly disrupt the topology of MyBP-C by causing protein misfolding that impairs protein function [14] . The N-terminal domains of MyBP-C -C0, C1 motif and C2 were previously found to play significant roles in regulating cardiac muscle contraction via their interaction with myosin [15] and actin [16] , while its C-terminus was recently reported to directly interact with cardiac ryanodine receptor type 2 (RyR2) [17] .
Considering the spectrum of HCM phenotypes described, we hypothesized that missense variation may disparately impact the structure of the protein and differentially affect its functional interactions [11, [18] [19] [20] ; hence, in this study we selected five c-MYBPC3 variants linked with HCM for structural and functional characterization. Three variants (V1-3) (V1, Arg177His; V2, Ala216Thr; V3, Glu258Lys) all located within the C1 domain, and V4 (Glu441Lys) within C2 domain were identified in an Egyptian HCM study [21] , while V5 is a double mutant (V3 & V4) that has been associated with a severe, early-onset HCM phenotype [11] . We hypothesized that these variants affect the biophysical and biochemical characteristics of MyBP-C, altering the functional properties of the C1 and C2 domains specifically leading to altered MyBP-C-actin association within the sarcomere. To characterize the in vivo effects of these variants, we employed a zebrafish model to elucidate morphometric consequences on cardiac function after synthetic mRNA injections. We also generated the mutant and wild-type N-terminal MyBP-C C0-C2 domains as recombinant proteins to examine their biophysical and biochemical properties, as well as their in vitro interaction with cardiac actin. Injection of zebrafish embryos with synthetic mRNA corresponding to the five MyBP-C variants produced atypical cardiac morphology and impaired cardiac function recapitulating the human HCM phenotype. Collectively, our results provide insight into the molecular impact of variant-specific c-MYBPC3 genotype on MyBP-C biophysical characteristics, protein stability and functional interaction with cardiac actin, contributing to a better understanding of HCM genotype-clinical severity correlation.
Experimental Materials and methods

Classification of identified variants
We used the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) for c-MYBPC3
variant selection with variable pathogenicity classification as: pathogenic, nonpathogenic, or as a variant of unknown clinical significance (unlikely to be pathogenic, uncertain, likely to be pathogenic).
Zebrafish model
All procedures were performed in conformity with the AAALAC International, Guidance on the housing and care of Zebrafish (Danio rerio) [22] . The study protocol was approved by Qatar University IACUC Office under project approval number QU-IACUC 015/2014. Zebrafish were raised and maintained at 28°C on a 14:10-h light-dark cycle and fed Artemia nauplii. Wildtype (AB) strain of zebrafish was used for our experiments. 
Morpholino design and synthetic mRNA injection
The c-mybpc3 morpholino (MO:5'-CTCTGGCATCCTGGTTGAGTGTCCC-3', Gene Tools, USA) targeted against the translational start site was injected into WT strain zebrafish embryos at one cell stage to knock down zebrafish endogenous c-mybpc3 [23] . In the mRNA experiments, c-mybpc3 MO (2.5 ng) was co-injected with human c-MYBPC3 mRNA (100 pg) for the corresponding missense c-MYBPC3 variants. At least 50 embryos were injected in each group.
Quantitative measurements of zebrafish cardiac size and function
Injected zebrafish embryos were raised at 28°C for 3 days and individually removed from the 28°C incubator immediately prior to measurement to minimize the effect of environmental temperature on cardiac function. Zebrafish embryos were mounted in 3% methylcellulose prior to imaging. The cardiac phenotypes were recorded at 60 frames/second for 3 seconds at 150 X using a stereomicroscope (SteREO Zeiss LUMAR.V12) equipped with USB 2.0 monochrome camera (The Imaging Source).
Measurement of zebrafish ventricular myocardial thickness
Structural analysis of the zebrafish ventricle was performed by analysis of 2D images at specific time points. Recorded videos were imported into Image J software (version 1.45s public domain software, http://imagej.nih.gov/ij) and ventricular end-diastole and ventricular endsystole images were extracted. The endocardial and myocardial boundaries were traced to calculate the ventricular wall thickness as the average thickness between these two regions.
Heart Rate Measurements
Recorded videos were imported into DanioScope software (Noldus, version 1.0.109) as a compressed AVI file, where a subset of the beating heart was outlined and heart rate was calculated.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 7. Multiple group comparisons were analyzed by one-way ANOVA. Significant difference between groups was expressed using p values: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Molecular Modeling
The complex MyBP-C structure of C1-C2 domains was obtained from our previous molecular dynamics study of 10ns simulations at physiological conditions, with all the parameters as described earlier [11] . The representative structures of WT MyBP-C and its variants from the molecular dynamics simulations were selected using cluster analysis. In this, 1000 structures of each variant trajectory were classified into clusters based on their structural deviations. A structure from the top ranked cluster was chosen for representation, as it was a frequently occurring conformation. These simulated structures utilized PyMol (www.pymol.org) for analysis of the secondary structural elements. To quantify the structural components, we used a secondary structure assignment program in PyMOL ("STRIDE") to calculate all the elements.
In addition, to map the structural deviations of variants from the WT, we used molecular superposition of the representative structures by aligning using the graphical interface in PyMOL. All protein cartoons were generated with high ray trace mode with depth cue to give 3D representation of the molecular models.
Plasmid construction
Human c-MYBPC3 cDNA (NM_001044349) was amplified by PCR from pcDNA-DEST47, using Phusion polymerase (Finnzymes) and the appropriate primers to incorporate 5'- [24, 25] . Cells were cultured at 37 °C until the optical density at 600 nm reached 0.6. Fusion protein expression was then induced for 18 h at 16°C with 0.1 mM IPTG (isopropyl β-D-thiogalactopyranoside). Bacterial cell pellets were harvested by centrifugation at 6,000 g for 15 minutes, 4°C and then resuspended in 20 ml of buffer A (50 mM Tris, pH 8.5, 300 mM NaCl, 25 mM imidazole). Cells were lysed by mild sonication then partitioned into soluble and insoluble fractions by centrifugation at 20,000 g for 20 minutes at 4°C and the supernatant containing the soluble protein fraction was transferred into a fresh tube. Supernatant was then applied to a 1ml Ni-NTA column pre-equilibrated in buffer A. To avoid auto-cleavage by intein protease, all the following purification steps were performed at 4°C using ice-cold buffers. After binding, the column was washed with 10 x column volumes of buffer A followed by an additional wash (10 x column volumes) of cleaving buffer (PBS buffer supplemented with 40 mM Bis-Tris and 25 mM imidazole, pH 6.0). After the second wash, the column was sealed and incubated at room temperature for 3 h to allow intein cleavage. After intein cleavage, 5 ml of cleaving buffer was used to elute the cleaved C0-C2 (MyBP-C) proteins from the resin. The remaining proteins bound to the column were eluted with 10 ml of cleaving buffer supplemented with 500 mM imidazole, and the eluted fractions were collected and analysed by 12% SDS-PAGE electrophoresis.
Western Blotting
Purified recombinant MyBP-C C0-C2 proteins were analyzed by SDS-PAGE electrophoresis with Coomassie Brilliant Blue staining and immunoblot analysis performed as described previously [26] . Proteins were probed with a polyclonal anti-MyBP-C antibody (1:1,000 dilution) (Abgent, Cat # AP12436a) and immunoreactive proteins were detected by ECL Chemiluminescence Detection Kit (Thermofisher Scientific, Cat #32106).
Circular Dichroism (CD) Analysis
CD measurements were conducted using a JASCO-715 spectropolarimeter with a Peltier type cell holder. Wavelength scans in the 190 nm to 260 nm range (far-UV region) were performed in Quartz SUPRASIL (HELLMA) precision cells of 0.1 cm path length, using a wavelength step of 0.2 nm, a scan rate of 20 nm min −1 , response time 1 s and 1 nm bandwidth.
Buffer spectra were collected and subtracted from all scans. The concentration of all protein samples was 0.2 mg/ml.
Thermal denaturation data were collected by heating the protein sample from 20° to 90°C using a scan rate of 1.5 K/min and monitoring signal changes at 208 nm. Spectral parameters for these measurements were: 1 s step resolution, 0.5 s response time, sensitivity 25 mdeg and bandwidth 1 nm. Data analysis software (CDNN version 2.1) was used to deconvolute the collected far-UV CD spectra in order to determine the protein's α-helix, anti and parallel β-sheet, β-turn and random coil content.
Chemical Denaturation
Fluorescence spectra were collected on a PTI QuantaMaster 400 steady-state fluorescence system. Tryptophan was selectively excited at 295 nm and emission spectra were collected between 310 to 450 nm using a 4 ml quartz cuvette (Hellma) with a path length of 10 mm. Scan rate was set to 100 nm min 
Co-sedimentation Cardiac Actin Binding Assays
Co-sedimentation assays were performed as previously described 
Results
c-MYBPC3 variants are associated with distinct HCM phenotype
The elucidation of genotype-phenotype associations provides a crucial parameter to help predict the impact of a specific variant on HCM clinical severity. To investigate the mechanism by which different c-MYBPC3 variants lead to cardiac impairment, we studied four single HCM patients expressing these variants exhibited a range of clinical symptoms and variable degrees of ventricular hypertrophy as determined by septum and wall thickness (Table 1) .
Multiple in silico algorithms, and/or population frequency databases defined the five variants' pathogenicity classification that varied from uncertain significance to certainly pathogenic.
Furthermore, the patient carrying the double mutation (V5) had an early-onset disease at age 21
and died at the age of 42. Conversely, patients carrying single mutations (V1, V2, V3, and V4)
had lower severity symptoms leading to heart failure later on in life (Table 1) suggesting that patients expressing different c-MYBPC3 variants can present with typical HCM clinical heterogeneity in regard to disease severity, onset and prognosis.
Modeling HCM patients' c-MYBPC3 variants using zebrafish
Zebrafish (Danio rerio) is a powerful vertebrate animal model to study cardiac function due to its embryonic transparency [29] . To assess variants' genotype-phenotype associations, we These results demonstrate that c-MYBPC3 V5 and V3 zebrafish cardiac phenotypes correlate with their pathogenicity classification in HCM patients, as both are predicted to be pathogenic class 5 (Table 1) . Thus, expression of these variants in the zebrafish model essentially recapitulated the HCM pathological cardiac phenotype in comparison to controls (Figure 2A-B) .
Zebrafish c-MYBPC3 models develop increased ventricular myocardial thickness
Cardiac morphometric measurement of the ventricular myocardial wall thickness of c-MYBPC3 variant-injected embryos was determined at both diastole and systole ( Figure 2C-D [30] .
Zebrafish c-MYBPC3 models develop impaired cardiac contractility
To examine whether the c-MYBPC3 variants elicit different effects on cardiac function,
we assessed the heart rate of injected zebrafish as an indicator of cardiac contractile impairment.
Introduction of both V3 and V5 synthetic mRNA significantly affected the average heart rate resulting in a 23% reduction for both groups; 113 beats per minute (bpm) compared to the level observed in zebrafish controls at 146 bpm. In contrast, there was a moderate decrease (<10%) for V1, V2, and V4, at 138, 143 and 133 bpm, respectively; however, these still represent cardiac contractile impairment ( Figure 2E ). These findings suggest that genotype specificity contributes to HCM phenotypic severity as the V5 double mutation produces early-onset and progression to end-stage HCM (Table 1) . Indeed, mRNA injection corresponding to V5 variant in zebrafish resulted in the most severe heart rhythm impairment ( Figure 2B -E).
Bioinformatics analysis of c-MYBPC3 variant effect on functional domains
The severe phenotypes of V3 and V5 led us to study structure-function relationships at protein level, which may reveal molecular determinants that underlie genotype to phenotypic expressions. Several studies have reported that the region C1-C2 of MyBP-C plays a central role in the interactions with actin and myosin proteins within the sarcomere [31, 32] . Our molecular model of the C1-C2 region of the WT protein suggests this linker segment (MyBP-C motif) may hold the key sites for protein phosphorylation ( Figure 3A) . The secondary structural elements of the domains C1 and C2 in the WT comprises β-sheets, however, the linker/motif is highlyhelical in nature. Both the V3 and V5 molecular models deviated structurally and were arranged differently from WT, with the majority of these rearrangements observed in the motif region ( Figure 3B-C) . The variants induced changes in the secondary structural elements of the C1 and C2 domains and in the intervening motif region, where the impact was in particular, higher in V5
( Figure 3C ) in comparison to V3. Interestingly, V3 appeared to be flexible, while V5 appeared to be rigid compared to WT in the RMSD (root mean square deviation) calculation of the representative structures from molecular dynamics simulations ( Figure 3D ). The secondary structural changes shown in the graph ( Figure 3E ) provides an overview of the intra-molecular consequences that induce structural rearrangements in both V5 and V3. Here, the V3 model presents reduced β-sheets and increased coils compared to WT, whereas V5 showed inverse behavior. This correlates with our deviation analysis and reflects V3 flexibility with increase of coils, and the rigid V5 upon reduction of coils with increased -sheets. Overall, this protein modeling helps to provide a molecular insight into the structural consequences of MyBP-C variants.
Circular dichroism (CD) spectroscopy and thermal stability analysis of MyBP-C variants
To investigate the impact of these c-MYBPC3 variants on the biophysical and biochemical properties of WT MyBP-C protein, we generated prokaryotic expression plasmid constructs encoding the C0-C2 N-terminal domains of WT and the five variants ( Figure 4A ). The purified recombinant C0-C2 fragment proteins were highly soluble and migrated on SDS-PAGE according to their predicted molecular weight of 50 kDa, as shown in both Coomassie stained gel and western blot analysis using MyBP-C N-terminal antibody ( Figure 4B ). To better understand the structural effects of these c-MYBPC3 variants, we measured far-UV CD spectra ( Figure 4C ) and we determined the secondary structure elements (Table 2 ) of all protein samples at 25°C. It was evident that all variants disrupted the native structure of the C0-C2 proteins, leading to conformations with significantly different secondary structure characteristics when compared to WT (Table 2) . At elevated temperatures (~90°C), all protein species retain most of their secondary structure characteristics (Supplemental material, Tables 1-6 ). However, for WT, V1 and V2, we observed an increase in random coil content with a concurrent loss of helicity, reflecting partial unfolding of the structure. At the same time, the β-sheet content of the protein fragments remained relatively intact, revealing a central core of β-sheets with high thermal stability. For V3, V4 and V5 only small changes in the secondary structure content were observed. This was also evident from the relatively small molar ellipticity change recorded in the far-UV spectra throughout the 20°C -90°C temperature range. Most likely, the observed changes involved spatial rearrangement of the secondary structure elements without significant unfolding.
CD melting curves were collected to analyze the thermal denaturation profiles at 208 nm over the temperature range 20°C -90°C ( Figure 5 ). The relative signal change for V3, V4 and V5 was small, resulting in curves with lower signal to noise ratio than the corresponding profiles of WT, V1, and V2. The thermal denaturation curve of WT, V1, V2, V3 and V4 revealed the presence of two consecutive unfolding transitions; the first thermal transition occurs in the temperature range 50°C -65°C with the second at 65°C -90°C. Interestingly, in contrast to other variants, the melting profile of V5 exhibits only the unfolding transition at 50°C -65°C, suggesting that no further protein aggregation occurred after ~60°C for this fragment. A possible mechanism for this complex thermal behavior involves the formation of oligomers from monomer protein fragments (first transition). As the temperature of the sample increases, partial unfolding and structural rearrangements of the proteins, dictated by further changes in their aggregation state, result in a second thermal transition. A similar thermal behavior has been previously reported for
other MyBP-C motifs [33, 34] with dynamic light scattering studies confirming the formation of aggregates upon heating [34] .
Chemical denaturation profiles for the WT and mutant MyBP-C proteins
To determine the thermodynamic stability of mutant MyBP-C protein fragments, we tested the reversibility of chemically-induced transitions to calculate the Gibbs free energy change (ΔG) of the unfolding process ( Table 3) . Chemical denaturation profiles of WT and MyBP-C recombinant fragment proteins exhibited transitions that were completely reversible and under thermodynamic control, with all samples recovering their initial spectra after dialysis into their original buffer ( Figure 6 ). Interestingly, except for V5, chemical denaturation of all variants lead to conformations with increased stability compared to the WT MyBP-C fragment.
Notably, V3 and V4 showed a significant increase in ΔG (~1.5 kcal/mol), while for V1 and V2
this change was less than 0.6 kcal/mol, slightly above the statistical error for these measurements. The recorded V5 destabilizing effect is small and lower than the corresponding statistical error, indicating that V5 has practically no impact on the thermodynamic stability of MyBP-C. Thermodynamic analysis for the chemical-induced denaturation of all fragments (Table 3) showed ΔG values lower than the typical 5-15 kcal/mol found for most proteins [27] .
MyBP-C variants affect cardiac function through impaired actin binding
MyBP-C is a multi-domain protein with vital structural and regulatory roles. The selected variants are located within the N-terminal region, which encompasses the C1-C2 domains of MyBP-C that is involved in regulating cardiac muscle contraction through interaction with actin within the sarcomere ( Figure 4A ). The recombinant C0-C2 domains have been previously shown to interact with actin [16] . Thus, we hypothesized that impaired cardiac function phenotypes may be correlated with a reduced ability of MyBP-C to interact with actin. To investigate the specific effects of the variant's structural alterations on actin binding properties, we employed a cosedimentation assay. In this assay, c-actin can be co-sedimented due to its filamentous nature, whereas non-filamentous or non-interacting proteins remain in the supernatant. In the absence of c-actin, WT MyBP-C C0-C2 recombinant protein remained in the supernatant fraction. However, when cardiac actin was added to the assay, WT MyBP-C C0-C2 recombinant protein specifically bound and co-sedimented with c-actin as the recombinant protein was detected in the pellet. 
Discussion
HCM is a genetically heterogeneous autosomal dominant cardiac disease [4, 35] , with many c-MYBPC3 variants previously reported in HCM patients [1, 8] . Since HCM clinical presentation in patients is also heterogeneous, it is hypothesized that severity is correlated to underlying genetic mutations. Previous studies demonstrated that patients carrying specific mutations have been associated with earlier disease presentation, poorer prognosis, severe disease phenotype, higher prevalence of a family history and sudden cardiac death [32, 36, 37] .
Furthermore, most of the childhood-onset disease mutations are missense (~76%), while ~60% of previously reported mutations in adults encode for MyBP-C truncations. This observation suggests that c-MYBPC3 missense mutations causing HCM may be more severe than truncating mutations, explaining the earlier age of onset [38] . Some studies have established potential correlations in interpreting the phenotypic effect of these variants. However, the exact mechanism by which these variants affect MyBP-C physiological functions within the sarcomere leading to the different clinical phenotypes still remains unclear.
Our current study presents a new model of an in vitro functional genomics approach to investigate the effects of specific genotypes on MyBP-C biophysical and biochemical characteristics that may explain HCM clinical severity. We selected five c-MYBPC3 variants ( Figure 1 ) that represented HCM heterogeneity with different pathogenicity classifications, as V3
and V5 (double mutant) were classified as the most pathogenic variants [11, [18] [19] [20] . Importantly, the double mutant V5 and the single mutant V3 exhibited the most severe myocardial hypertrophic phenotype (Table 1 ). Molecular modeling suggested critical structural consequences for these two variants (Figure 3) . Furthermore, our biophysical analysis revealed that all variants lead to distinct protein conformations affecting the secondary structure content These results support the established class 5 pathogenicity of these two variants (Table 1) .
Collectively, our zebrafish functional validation suggests an association of genotype to a disease phenotype; and confirmed the in-silico tools of pathogenicity classification of a specific genetic variant. Our findings support previous studies of other MyBP-C variants associated with a severe clinical phenotype [39] . Previous studies have demonstrated that each individual c-MYBPC3
patient's phenotype varies with the position of the mutation and its cognate functional domain. It has been suggested that possessing multiple disease-causing sarcomere mutations may be associated with a greater risk for severe disease progression, including sudden cardiac death.
This can be interpreted as double (or compound) variants exerting a gene dosage effect in HCM patients [9, 37, 40] . Recent reports using molecular modeling together with clinical and expression data revealed that the missense mutations in the C1-C2 of MyBP-C could be responsible for the severe symptoms studied in selected HCM patients [11, 13, 32] . Accordingly, our study particularly highlights the variants-induced secondary structural modifications in detail and reveal conformational rearrangements of the variants V3 and V5 (enhanced impact), which lead to severe effects on the motif region. As reported previously by many studies [31, 41] , this motif is a key location for protein phosphorylation and for interaction with actin and/or myosin which serve to regulate the mechanism of muscular contractions. Therefore, the observed data from our modeling and CD-spectroscopy collectively suggest variation-induced secondary structural changes could be detrimental to function, explaining the abnormal phenotypes that we observed in our diseased models of zebrafish. Earlier molecular modeling suggested that V1 and V2 might increase the intra-molecular rigidity due to induced structural changes, resulting in minimal effect on the surface electrostatic properties that are key for binding with actin [13] .
Contrastingly, V3 was predicted to significantly alter the structural properties leading to major change in C1 surface and malfunction of the protein [42] . Significantly, modeling of V5 conformational changes of C1-C2 domains predicted alterations of the binding of these domains to other MyBP-C domains and other sarcomeric proteins (actin and myosin), in particular by affecting the nearby motif region. These effects possibly explain the early onset and the severity of the observed HCM phenotype [11] .
By using the zebrafish model to study the effects of these MyBP-C variants, our data indicate correlation of phenotypic variations to specific molecular mechanisms of altered protein characteristics and binding interactions with c-actin. The recombinant N-terminal, C0-C2 fragment, of V5 and V3 confirmed the model of altered secondary structural elements of the protein. As a result, V5 had only one unfolding transition step in the thermal denaturation curve compared to the other variants, which demonstrated two consecutive unfolding transitions. These observations highlight the fact that these missense variants result in altered protein conformations, which could potentially affect MyBP-C physiological functions within the sarcomere. MyBP-C is a multi-modular structural protein of 11 domains regulating sarcomere organization and contractility [1, 15, 43, 44] . It was previously shown that the N-terminal complex, C1-C2 of MyBP-C, regulates cardiac muscle contraction through actin interaction within the sarcomere [15, 28, 45, 46] . Our in vitro MyBP-C/cardiac actin co-sedimentation assays confirmed the negative effect of V2, V3, V4 and V5 mutations on the intermolecular interactions of MyBP-C with c-actin and more importantly highlighted the severe effect of the double mutation, V5. Accordingly, V5 relative binding affinity to c-actin was reduced almost 52% when compared to that of WT. In contrast, V1 variant did not exhibit any significant reduction on its relative binding affinity to c-actin suggesting alternative disease mechanisms rather than altered c-actin binding affinity. As recent studies have shown a significant overlap between the N-terminal of MyBP-C and actin as well as myosin S2 binding sites [47] , further analysis should be considered to study the impact of these variants on their interaction with myosin. Interestingly, despite the fact that we detected a significant reduction of V3 relative binding affinity to c-actin (~27%), earlier studies using the yeast two-hybrid system indicated that MyBP-C N-terminal E258K variant (V3) had reduced affinity to myosin heavy chain subfragment 2, providing a potential alternative mechanism underlying the HCM disease phenotype [48] . Our findings might begin to explain the contractile dysfunction resulting from the different c-MYBPC3 variants as a result of their divergent biochemical and biophysical characteristics.
Interestingly, the effect of the five mutations on cardiac phenotype in our experimental zebrafish model is consistent with previously reports on the patients' clinical severity.
Conclusion
Although MyBP-C protein has been extensively studied, the exact molecular mechanism(s) by which MyBP-C missense variants lead to severe cardiac disease remain elusive. This is largely due to the lack of a comprehensive understanding of the impact of these mutations on the protein molecular characteristics, as well as on its interactions with other sarcomeric components.
Our current study has clearly demonstrated that the zebrafish model is a very useful in vivo 'tool' to prognose and characterize the pathogenicity of MyBP-C missense mutations identified in patients with cardiac disease. It also provides further evidence for the important role Cardiac functional analysis of variants expressed in zebrafish, the measurement of ventricular diastolic myocardial thickness for V5 (double mutation E441K & E258K) and V3 (E258K) were the most significantly increased mean followed by V1 (R177H), V4 (E441K) and V2 (A216T) in comparison to WT. D. Ventricular systolic myocardial thickness measurement for V5 were the most significantly increased mean at 14.6 μm followed by V3, V1, V4 and V2 in comparison to
WT. E. Heart contractile measurement showed that both V5 and V3 significantly impacted the average heart rate in injected zebrafish demonstrated by the significant reduced heart rate mean measured by beats per minute (bpm) compared to WT. While, V1, V2 and V4 heart rates were still less than the control zebrafish. Cardiac function analyses were represented in Box -Whisker plots and analysis using one-way ANOVA multiple comparisons test. Values were expressed as means ± SE and p values of < 0.05 were considered statistically significant, a value of **p<0.01, ***p<0.001 and ***p<0.0001. were calculated by comparison to the binding of WT MyBP-C C0-C2 using an unpaired Student's t-test. n = 2 ± S.E.M., *p<0.05 and **p<0.01, (GraphPad Prism 7). 
